Rallying to the Challenge 2024 - Day 2
Dr Alan Whone, University of Bristol

Dr Alan Whone from the University of Bristol discusses the set-up and results from the phase 1b trial of GDNF - a neurotrophic factor - for Parkinson's, as well as the upcoming phase 2 trial of the same therapy, titled "REGENERATE PD". The therapy is created by the pharmaceutical company AskBio and differs from previous GDNF trials as it uses gene therapy approach to administer GDNF.

REGENERATE PD is now recruiting participants in the US and UK. If you are interested in participating, please speak to your neurologist, review the information on clinicaltrials.gov/study/NCT06285643 or foxtrialfinder.michaeljfox.org, and/or email AskBio at [email protected].

This talk was given as a part of the Rallying to the Challenge meeting, hosted by Cure Parkinson's and the Van Andel Institute in Grand Rapids, Michigan on September 23-24, 2024. Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates, and care partners to explore how the Parkinson’s community can impact and accelerate research. It is a part of the larger Grand Challenges in Parkinson's Disease meeting, an annual scientific symposium for Parkinson's research.